Results 171 to 180 of about 513,228 (356)

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Broadening the Clinical Spectrum of Axonal Hereditary Neuropathies: A Comparative Case Study on DNAJB2- and HINT1-Related Disease. [PDF]

J Peripher Nerv Syst
Bjelica B, Hendrich C, von Hardenberg S, Vukojevic M, Körner S, Gschwendtberger T, Haghikia A, Peric S, Petri S.   +8 more
europepmc   +1 more source

Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes

, 2015
Hanna Shevalye, Matthew S. Yorek, Lawrence J. Coppey, Amey Holmes, Matthew M. Harper, Randy H. Kardon, Mark A. Yorek   +6 more
openalex   +2 more sources

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. [PDF]

J Peripher Nerv Syst
Cebulla N, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L, Güse J, Giordani N, Wieser A, Schoch F, Reinle ML, Gommersbach S, Papagianni A, Zhou X, Einsele H, Reinhold AK, Rittner H, Kortüm KM, Sommer C.   +18 more
europepmc   +1 more source

On the interplay between cochlear gain loss and temporal envelope coding deficits [PDF]

, 2016
AC Furman, BC Moore, DW Purcell, GR Long, H Bharadwaj, H Bharadwaj, M Mauermann, PA Dorn, SG Kujawa, Z Zhong   +9 more
core   +2 more sources

Ischemic neuropathy and rhabdomyolysis as presenting symptoms of postpartum cardiomyopathy [PDF]

, 2008
Rick C. Helmich, Hanneke W.M. van Laarhoven, Hennie C. Schoonderwaldt, Mirian C. H. Janssen   +3 more
openalex   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source